Neurocrine (small cell) cancer of the prostate: an update

A new review article in the open access journal Oncology offers some key information about neuroendocrine (small-cell) carcinomas of the prostate (and why they offer essential lessons about the diagnosis and management of prostate cancer). … READ MORE …

NICE rejects Provenge as a treatment for mCRPC based on cost

The National Institute for Health and Clinical Excellence (NICE) in the UK has issued a statement that, according to preliminary draft guidelines, it has rejected the use of sipuleucel-T (Provenge) to treat patients with metastatic prostate cancer before they have received chemotherapy. … READ MORE …

Chimeric antigen receptor T-cell (CART) therapy: current data, future potential

An article in today’s issue of the New England Journal of Medicine reports data from a Phase II trial of CART therapy in the treatment of patients with acute lymphoblastic leukemia or ALL (an aggressive and difficult to treat form of cancer). This is arguably one of the most exciting papers on the treatment of cancer in the past 50+ years. … READ MORE …

Evolution of the mCRPC treatment landscape

A new article by Jeffress in the cancer business publication OBR Green discusses the changing patterns of use of  the various approved drugs in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Expert opinions on prevention, screening, and active surveillance

There are three new and useful resources now available related to the prevention of prostate cancer, screening for prostate cancer, and the role of active surveillance in the expectant management of prostate cancer. … READ MORE …

Testosterone supplements, rats, and risk for prostate cancer in healthy, aging men

The “New” Prostate Cancer InfoLink has long argued that the use of testosterone supplements by otherwise healthy men as they age (as a way to try to maintain the vigor and libido of their youth) comes with risks, and that one of those risks is the risk for a diagnosis of prostate cancer. … READ MORE …

Current options for treatment of radiorecurrent, localized prostate cancer

For men who choose to have radiotherapy (external photon beam, external proton beam, or brachytherapy of some type) as first-line therapy for localized prostate cancer, a major issue is, “What if the cancer recurs after treatment?” … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,154 other followers